Grants and Contracts Operations Branch (GCOB)

U19 CA52955

08/01/05-04/30/10

Phillip O. Crews, Ph.D.

University of California, Santa Cruz, CA

Targeted Discovery of Marine-derived Anticancer Leads

Robert Schlege, Novartis Institutes of Biomedical Research, Inc.; William H. Gerwick, Oregon State Univ.; Amy E Wright, Harbor Branch Oceanographic Institute; William Fenical, Scripps Institute of Oceanography

U19 CA67786

09/26/05-04/30/2010

Chris M. Ireland, Ph.D.

University of Utah, Salt Lake City, UT

Anticancer Agents from Unique Natural Products Sources

Lee Greenberger, Guy Carter, Semirami Ayral-Kaloustian, Wyeth Pharmaceuticals; John H. Clardy, Harvard Univ.; Raymond J. Andersen, Univ. of British Columbia

U19 CA11341

09/09/05-04/30/2010

Elisabeth M. Jaffee, M.D.

Johns Hopkins University, Baltimore, MD

Combinational Immunotherapies to Amplify Vaccine Induce*

T.C. Wu, Drew Pardoll, Lieping Chen, Johns Hopkins Univ.

U19 CA113298

08/19/05-04/30/2010

Kit S. Lam, M.D.

University of California-Davis, Sacramento, CA

Targeting Agents for Human and Canine Lymphoma

Yoshikazu Takada, Sally DeNardo, Univ. of California-Davis

U19 CA52995

09/29/05-04/30/2010

Garth Powis, D. Phil

Arizona Cancer Center, Tucson, AZ

Cancer Drugs Active Against Stress Signaling Pathways

Robert T. Abraham, Peter Houghton, Mary-Ann Bjornsti, St. Jude Children's Hospital; John S. Lazo, Univ. of Pittsburgh

U19 CA113318

08/15/05-04/30/2010

John C. Reed, M.D.

Burnham Institute, La Jolla, CA

Apoptosis-Based Cancer Drug Discovery

Dennis Carson, Univ. of California San Diego; Maurizio Pellechia, The Burnham Institute

U19 CA67771

05/27/05-04/30/2010

Saïd M. Sebti, Ph.D.

H. Lee Moffitt Cancer Center & Research Institute, Drug Discovery Program, Tampa, FL

Inhibitors of Rho Function as Novel Cancer Therapeutics

Andrew D. Hamilton, Yale Univ.; Nicholas J. Lawrence, Moffitt Cancer Center; Adrienne Cox and Channing Der, Univ. of North Carolina at Chapel Hill

U19 CA113297

06/21/05-04/30/2010

Ben Shen, Ph.D.

University of Wisconsin-Madison, Madison, WI

UWCCC National Cooperative Drug Discovery Group for Cancer

Jon S. Thorson, Paul F. Lambert, F. Michael Hoffman, Univ. of Wisconsin

U19 CA113317

07/01/05-04/30/2010

Shaomeng Wang, Ph.D.

University of Michigan, Ann Arbor, MI

Novel Small-Molecule Inhibitors of Bcl-2/Bcl-xL Protein*

Jeanne Stuckey, Kenneth J. Pienta, Univ. of Michigan

Agent

Major Accomplishment:

Topotecan (1996)

This agent was developed by the NCDDG headed by Warren Ross, University of Florida at Gainesville. Much of the developmental work was supported by SmithKline Beecham, the pharmaceutical partner in the project. Topotecan, a semi-synthetic, water-soluble analog of the natural product camptothecin, is an inhibitor of topoisomerase I. It has been approved for use for the treatment of ovarian and breast cancer.

Gliadel (1996)

This treatment was developed by the NCDDG headed by Henry Brem, Johns Hopkins University, for the treatment of brain tumors, particularly glioblastoma multiforme, a tumor that frequently recurs at the same site. The product consists of BCNU impregnated in a wafer composed of a polyanhydride biodegradable polymer invented by Robert Langer of MIT. Wafers are implanted at the time of surgical resection of the tumor. Over time the drug diffuses away from the polymer, which eventually degrades. The product received marketing approval in 1996 in the United States and later was approved in Brazil, Canada, and several European countries. The product is manufactured by Guilford Pharmaceuticals, an exclusive licensee of MIT, and is being distributed by Aventis.

DAB389IL-2 (1998)

This fusion protein is composed of the catalytic and transmembrane domains of diptheria toxin and IL-2. It was created by the NCDDG organized by John Murphy, The University Hospital, Boston, in collaboration with Seragen, Inc., Hopkinton, MA. This product has been shown to be safe and well tolerated and to induce durable complete and partial remissions in hematologic malignancies that are characterized by the expression of high affinity IL-2 receptors. The product, which is also known as ONTAK, Interleukin-2 Fusion Protein or Denileukin difitox, is approved for the treatment of adult patients with recurrent or persistent cutaneous T cell lymphomas. Ligand Pharmaceuticals Inc. of San Diego, CA acquired the marketing rights from Seragen Inc.

Agent

Major Accomplishment:

N¹,N ¹⁴-diethylhomospermine (SunPharm) and

N¹,N ¹¹-diethylnorspermine (Parke-Davis, a division of Warner-Lambert)

These are polyamine analogs synthesized by the NCDDG headed by Carl Porter, Roswell Park Memorial Institute. These compounds, prepared by Raymond Bergeron, disrupt polyamine homeostasis. Diethylhomospermine (DEHOP) is being evaluated in a Phase II trial in AIDS patients with uncontrolled, refractory diarrhea. Diethylnorspermine has entered Phase II clinical trials for the treatment of solid tumors.

O⁶-Benzylguanine (OBG)

OBG was identified and evaluated by the NCDDG guided by Anthony Pegg, The Milton S. Hersey Medical Center. It was selected from a series of compounds synthesized by Robert Moschel at NCI Frederick. OBG entered NCI-sponsored clinical trials in combination with BCNU as a means of blocking repair of DNA adducts by alkylguanine transferase, a protein responsible for a major mechanism of resistance to BCNU and similar agents.

Cryptophycin

This novel depsipetide was isolated by Robert Moore, University of Hawaii, from blue-green algae and was found to have potent antiproliferative and antimitotic properties that differ from those of Taxol. This project was coordinated by the NCDDG organized by Frederick Valeriote, Wayne State University, with Eli Lilly as a pharmaceutical partner. A semi-synthetic analog, Compound #52, has entered Phase II clinical trials under sponsorship of Eli Lilly. Lilly chemists developed a total synthesis procedure in a collaborative effort between natural product and medicinal chemists.

Cordycepin and Deoxycoformycin

These compounds entered Phase I clinical trials for the eventual treatment of lymphoblastic leukemias and lymphomas which contain terminal deoxynucleotidyl transferase (TdT), a unique DNA polymerase which catalyzes the polymerization of deoxyribonucleotides on the 3'-hydroxyl ends of preformed oligo- or polydeoxynucleotide initiators, without the need of a template. Cordycepin inhibits TdT if its own metabolism is blocked by deoxycoformycin, an inhibitor of adenosine deaminase. This project was conceived and brought to trial by the NCDDG headed by Ronald McCaffrey, The University Hospital, Boston.

Murine Anti-Transferrin Receptor Monoclonal Antibodies (A27,15/E2.3)

IND closed 2001

These antibodies were discovered on the Mendelsohn NCDDG by Ian Trowbridge, Salk Institute. The products entered Phase IA clinical trails at the University of Arizona in Tucson under the supervision of Dr. Raymond Taetle. The antibodies are administered as a combination in a 1:1 ratio based on preclinical studies which showed that the most effective inhibition occurred when the products were given as a pair, presumably by cross-linking the transferrin receptor.

Anti-EGF Receptor Antibody (C225)

This agent was developed by John Mendelson (originally at Memorial Sloan-Kettering Cancer Center but now at M.D. Anderson Cancer Center) with support from the NCDDG and other sources. This human-mouse chimeric product is being combined with chemotherapeutic agents, such as cisplatin, or with radiation. Clinical trials are in progress for the treatment of colon cancer and refractory advanced squamous cell head and neck carcinoma. This work builds on an original hypothesis developed by John Mendelson in the early 1980s that blocking EGF receptors with a monoclonal antibody prevents receptor activation. Phase III trials of C225 were initiated in 1999 by ImClone Systems, Inc. of New York in collaboration with Merck KGaA of Darmstadt, Germany. In 2001 Bristol-Myers Squibb and ImClone Systems agreed to co-develop IMC-C225, which is now called Erbitux^TM (cetuximab). In November 2001, ImClone Systems submitted a Biologics License Application (BLA) to the FDA for Erbitux for the treatment of advanced colon cancer that is refractory to irinotecan.

A Farnesyl Transferase Inhibitor

This agent was developed by the NCDDG headed by Said Sebti, University of South Florida, Tampa, FL. Based on the peptide structure of the CAAX box, this Group synthesized and evaluated a series of peptidomimetics. This Group was the first to publish the antitumor properties of this class of compounds in human xenograft models and to demonstrate, contrary to earlier expectations, that the Ras protein is probably not the target nor the determinant of antitumor activity. One derivative entered Phase I clinical trials under sponsorship of Abbott Laboratories but was later dropped when the orally administered drug did not achieve required blood levels. The Sebti group is currently developing plans to reformulate the drug for intravenous administration and is also examining close analogs for possible development.

A Vaccine for Prostate Cancer (Provenge)

This vaccine was developed by Dr. Riner Laus, Dendrion Corp., Seattle, WA, in Ronald Levy’s NCDDG and has currently completed Phase II evaluation under the direction of Dr. Eric Small at the University of California at San Francisco (J. Clinic. Oncol.18, 2000, pp 3894-3903). Their approach is to isolate a patient’s dendritic cells, pulse them with a peptide derived from prostatic acid phosphatase, and re-administer the modified dendritic cells back to the patient. They are proceeding to a randomized Phase III trial based on a notable decrease in disease progression.

No./Performance

Period

P.I./Institution

Title

Collaborators

U19 CA52857

06/15/90-04/30/05

Henry Brem, M.D.

Johns Hopkins School of Medicine

Baltimore, MD

Controlled Release Polymers for Brain Tumors

Drew Pardoll, Johns Hopkins; O. Michael Colvin, Duke Univ. Medical Center; Robert S. Langer, MIT; W. Mark Saltzman, Yale Univ.

U19 CA67842

09/20/95-09/30/04

Allison C. Chin, Ph.D.

Geron Corporation

Menlo Park, CA

Telomerase: A Molecular Target for Cancer Therapy

Richard L. Tolman, Geron Corp.; Malcolm A.S. Moore, Memorial Sloan-Kettering Cancer Ctr.

U19 CA52955

09/01/90-04/30/05

Phillip Crews, Ph.D.

University of California, Santa Cruz

Santa Cruz, CA

Molecular Approaches to Discover Marine Natural Product Anticancer Leads

Dennis France, Novartis Institute for Biomedical Research; William H. Gerwick, Oregon St. U.; Amy E. Wright, Harbor Branch Oceanographic Institute

U19 CA67775

09/08/95-04/30/05

William Fenical, Ph.D.

Scripps Institution of Oceanography

University of California, San Diego, La Jolla, CA

New Anticancer Drugs from Cultured and Collected Marine Organisms

D. John Faulkner, Scripps Inst. of Oceanography, UCSD; Yuzuru Shimizu, U. of Rhode Island; Robert Kramer, Bristol-Myers Squibb Pharmaceutical Research Institute

U19 CA87427

09/27/00-04/30/05

Jose A. Halperin, M.D.

Harvard Medical School

Laboratory for Membrane Transport, Boston, MA

New Translation Initiation Inhibitors for Cancer Therapy

William Christ, Gerhard Wagner, Harvard Medical School

U19 CA50771

09/29/89-05/31/05

Sidney M. Hecht, Ph.D.

University of Virginia

Charlottesville, VA

Natural Products Discovery - Nuclear & Signaling Targets

John S. Lazo, U. of Pittsburgh; David G. I. Kingston, VPI & State U.; Steven C. Bobzin, Galileo Laboratories

U19 CA67786

09/08/95-04/30/05

Chris M. Ireland, B.A., Ph.D.

University of Utah

Salt Lake City, UT

Anticancer Agents from Unique Natural Products Sources

Philip Frost, William M. Maiese, Jerauld S. Skotnicki, Wyeth-Ayerst Research; Jon. C. Clardy, Harvard; Raymond J. Andersen, U. of British Columbia

U19 CA72108

09/30/96-04/30/04

Elizabeth Marion Jaffee, M.D.

Johns Hopkins University

School of Medicine

Baltimore, MD

Antigen-Specific Vaccines for Breast Cancer

Drew Pardoll, Tzyy-Choou Wu, Johns Hopkins; Yvonne Paterson, Univ. of Pennsylvania School of Medicine

U19 CA52956

09/01/90-04/30/05

Alan Douglas Kinghorn, Ph.D., D.Sc., Univ. of Illinois at

at Chicago, Chicago, IL

Novel Strategies for Plant-Derived Anticancer Agents

Norman R. Farnsworth, U. of Ill. at Chicago; Mansukhlal C. Wani, RTI; Robert A. Kramer, Bristol-Myers Squibb Pharmaceutical Research Institute

U19 CA87525

9/30/00-05/31/05

Alfred H. Merrill, Jr., Ph.D.

Georgia Institute of Technology

Atlanta, GA

Naturally Occurring Sphingolipids and Spingolipid Analogs as Mechanism-based Anti-cancer Agents

Dennis C. Liotta, David Pallas, Emory Univ.

U19 CA67763

9/08/95-04/30/05

William Booth Parker

Southern Research Institute

Birmingham, AL

Tumor Sensitization to Purine Analogs by E. coli PNP

Steven E. Ealick, Cornell Univ.; John A. Secrist, III, Southern Research Institute; Eric J. Sorscher, U. of Alabama at Birmingham

U19 CA52995

08/08/90-04/30/05

Garth Powis, D. Phil

Arizona Cancer Center

Tucson, AR

Anticancer Drugs Active Against Cell Cycle and Signal Pathways Targets

Robert Abraham, Burnham Institute; John Lazo,

Univ. of Pittsburgh

U19 CA67771

09/01/95-04/30/05

Saïd M. Sebti, Ph.D.

Lee Moffitt Cancer Center & Research Institute, Drug Discovery Program, Tampa, FL

Geranylgeranyltransferase I Inhibition and Cancer Therapy

Andrew D. Hamilton, Yale Univ.; Adrienne Cox, Univ. of North Carolina

U01 CA45967

09/03/87-05/31/92

Michael G. Brattain, Ph.D.

Baylor College of Medicine

Houston, TX

Growth Regulation of Human Colonic Neoplasms

J.K.V. Willson, Case Western Reserve Univ.; Y.S. Kim, Univ. of CA at San Francisco; L.C. Yeoman, Baylor College of Medicine; Bristol-Myers Squibb Co.

U01 CA50743

7/15/89-04/30/94

Ching-jer Chang, Ph.D.

School of Pharmacy

Purdue University

Lafayette IN

Mechanism-Based Discovery of Antitumor Agents

Curtis L. Ashendel, Robert L. Geahlen, Purdue Univ.

U01 CA50750

09/01/89-06/30/94

Jon C. Clardy, Ph.D.

Cornell University

Ithaca, NY

New Anticancer Drugs from Cultured and Collected Marine Organisms

Anna-Maria Casazza, Bristol-Myers Co.; D. John Faulkner, William Fenical, Scripps Inst. of Oceanography; Chris Ireland, Univ. of Utah; Yuzuru Shimizu, Univ. of Rhode Island

U01 CA45962

09/10/87-07/31/90

Thomas H. Corbett, Ph.D.

Wayne State University

School of Medicine

Detroit, MI

Drug Discovery - Anticancer Agents for Colorectal Cancer

Paul Cavanaugh, Eastman Kodak/Sterling Drug (replaced Paul Aristoff and Pat McGovern, The Upjohn Co.); Frederick Valeriote, Gordon Luk, Wayne State Univ.

U01 CA52956

09/30/90-09/29/95

Geoffrey A. Cordell, Ph.D.

Univ. of Illinois at Chicago,

Chicago, IL

(replaced by: A. Douglas Kinghorn)

Novel Strategies for Plant-Derived Anticancer Drugs

Norman R. Farnsworth, A. Douglas Kinghorn, John M. Pezzuto, Univ. of Ill. at Chicago; Monroe E. Wall, Research Triangle Inst.; Timothy J.R. Harris, Glaxo Group Research Ltd.

U01 CA57714

09/30/92-09/29/95

J. Gordon Foulkes

Oncogen Science, Inc.

Uniondale, NY

Development of Novel Drugs for PH1 Positive Leukemia

Collin Goddard, Oncogen Science, Inc.; Barry Katz, MYCOsearch, Inc.; John A. Slack, Aston Molecules, Ltd.; John Groffen, Children’s Hospital of Los Angeles; Richard Van Etten, Center for Blood Research

U01 CA51880

06/07/90-05/31/95

L. L. Houston, Ph.D.

Cetus Corp.

Emeryville, CA

Engineered Antibreast Cancer Single-Chain FV Immunotoxin

James S. Huston, Creative BioMolecules;

Louis M. Weiner, Fox Chase Cancer Ctr.;

Walter F. Stafford, Boston Biomedical Research Ctr.

U01 CA46088

09/30/87-05/31/92

Michael R. Johnston, M.D.

Univ. of Colorado Health Sciences Ctr.

Denver, CO

National Cooperative Drug Discovery Group for Lung Cancer

Paul A. Bunn, Univ. of Colorado Health Sciences Ctr.; Christopher A. Dawson, Zablocki V.A. Medical Ctr.; Edward L. Gillette, Colorado State Univ.

U19 CA 53617

05/01/90-09/29/01

Victor A. Levin, M.D.

University of Texas/M.D. Anderson Cancer Center

Houston, TX

Development of Drug Inhibitors of Src

John S. McMurray, Raymond Budde; Robert Newman, Gary Gallick, U. of Texas, M.D. Anderson Cancer Ctr.; Johnathon Ellman, Univ. of Calf, Berkley

U01 CA 37655

08/01/84-1988

Victor A. Levin, M.D.

Northern California Cancer

Center

Approaches to Inhibition of Oncogene

Expression

J. Michael Bishop, George Kenyon, U. of California,

San Francisco; Paul Bartlett, U. of California, Berkeley; David Stringfellow, Bristol-Myers

U19 CA72103

9/30/96-09/30/01

Ronald Levy, M.D.

Stanford Univ. Medical Center

Stanford, CA

GM-CSF Fusion Proteins and

Dendritic Cells as Tumor Vaccines

Edgar G. Engleman, Stanford Univ.; Reiner Laus, Activated Cell Therapy

U01 CA51908

05/21/90-04/30/95

Marc E. Lippman, M.D.

Lombardi Cancer Research Center, Georgetown University

Washington, D.C.

Growth Regulation as Targets in Breast Cancer Treatment

Mary Beth Martin, Edward A. Sausville, Robert Clarke, Anton Wellstein, Robert Dickson, Georgetown Univ.

U01 CA52020

06/01/90-05/31/93

Ronald P. McCaffrey, M.D.

University Hospital, Boston University, Boston, MA

Specific Therapy for TdT-Positive Leukemia/Lymphoma

G. Peter Beardsley, Yale Univ. School of Medicine; Chung K. Chu, Univ. of Georgia

U01 CA51992

06/15/90-05/31/95

Frank McCormick, Ph.D.

Cetus Corporation

Emeryville, CA

Discovery of Drugs Inhibiting Oncogenic RAS Proteins

Alfred Wittinghofer, Max Planck Inst.; Alfred Redfield, Brandeis Univ.; Alexander W. Wood, Hoffmann-LaRoche

U19 CA37641

08/01/85-08/31/98

John Mendelsohn, M.D.

Univ. of Texas, M.D. Anderson Cancer Ctr.Houston, TX

(replaced by: Raymond Taetle)

University of Arizona,

Tucson, AZ)

Antireceptor Monoclonal Antibodies in Cancer Treatment

Ralph A. Reisfeld, The Scripps Research Inst.; Raymond Taetle, Univ. of Arizona; Ian S. Trowbridge, The Salk Inst. of Biological Studies; Hideo Masui,

Memorial Sloan-Kettering

U19 CA48626

09/01/95-08/31/98

John R. Murphy, Ph.D.

University Hospital, Boston

University, Boston, MA

IL-7 & IL-7R Targeted Therapeutic Agents for Leukemia

Francine Foss, Boston Univ. Medical Ctr. Hospital; Benjamin Rich, Brigham & Women’s Hospital;

Cory A. Waters, Seragen, Inc..

U19 CA48626

09/30/88-07/31/93

John R. Murphy, Ph.D.

University Hospital, Boston

University, Boston, MA

Growth Factor Receptor Targeted Toxins for Leukemia/Lymphoma

Ronald McCaffrey, Univ. Hospital, Boston U.; Terry B. Strom, Beth Israel Hospital; Vicki E. Kelley, Brigham & Women’s Hospital; Jean Nichols, Seragen Corp.

U19 CA72108

09/30/96-09/29/00

Drew M. Pardoll, M.D., Ph.D.

Johns Hopkins University,

Baltimore, MD

Antigen Specific Vaccines for Breast and Cervical Cancer

T.C. Wu, Elizabeth Jaffe, John Hopkins; Yvonne Paterson, U. of Pennsylvania

U19 CA57725

08/17/92-09/29/01

Anthony E. Pegg, Ph.D.

Penn State University

Hershey, PA

Inhibition of DNA Repair to Enhance Chemotherapy

M. Eileen Dolan, The Univ. of Chicago Medical Ctr; Henry S. Friedman, Duke Univ. Medical Center; S. Clifford Schold, Univ. of Texas Southwestern Medical Ctr.; Stanton L. Gerson, Case Western Reserve Univ.

U01 CA37606

09/01/84-08/31/92

Carl W. Porter, Ph.D.

Grace Cancer Drug Center

Roswell Park Memorial Inst.

Buffalo, NY

Inhibitors of Polyamine Biosynthesis and/or Function

Raymond J. Bergeron, Univ. of Florida at Gainesville; James K. Coward, Rensselaer Polytechnic Inst.; Janice R. Sufrin, Roswell Park Memorial Inst.; Anthony E. Pegg, Hershey Medical Ctr.; Laurence J. Marton, Univ. of California at San Francisco; Robert A Casero (replaced Steve Baylin), Johns Hopkins Univ. School of Medicine; Gordon Luk, Harper Hospital, Detroit, MI

U01 CA51946

08/01/90-07/31/93

Ralph A. Reisfeld, Ph.D.

Research Institute of Scripps Clinic, La Jolla, CA

New Tumor Models for the Development of Immunotherapy

Stephen D. Gillies, Damon Biotech, Inc.; Barbara M. Muller, Research Institute of Scripps Clinic

U01 CA40884

07/01/85-06/30/90

Warren Ross, M.D.

University of Florida

Gainesville, FL

Topoisomerases as New Therapeutic Targets

Leroy F. Liu, Johns Hopkins Univ.; Robert Hertzberg, Randall Johnson, Smith, Kline & French Labs.; Timothy MacDonald, Univ. of Virginia

U01 CA57723

08/21/92-07/31/96

Sydney E. Salmon, M.D.

Univ. of Arizona College of

Medicine, Tucson, AZ

Discovery of Peptide Anticancer Drugs

Michal Lebl, The Selectide Corp.; Axel Ullrich, Max-Planck Inst.; Kit S. Lam, Arizona Cancer Ctr.; Joseph Schlessinger, New York Univ.; Victor Hruby, Univ. of Arizona

U19 CA67861

09/08/95-08/31/00

Michael I. Sherman, Ph.D.

PharmaGenics, Inc.

Allendale, NJ

(replaced by: Katherine Klinger, Genzyme Corp., Framingham, MA)

Discovery of Natural Products that Restore p53 Function

Michael Moore, Xenova Ltd.; Arthur Bertelsen, PharmaGenics, Inc.; Nikola Pavletich, Memorial Sloan-Kettering Cancer Ctr.

U01 CA51958

06/01/90-05/31/93

Zenon Steplewski, M.D., Ph.D.

The Wistar Institute

Philadelphia, PA

Radioisotope-Antibody Conjugates for Cancer Therapy

Peter Curtis, The Wistar Inst.; Leonard F. Mausner,

James F. Hainfeld, Brookhaven National Laboratory

U01 CA60130

08/27/92-07/31/96

Donald L. Trump, M.D.

University of Pittsburgh

Pittsburgh, PA

(replaced by: Eric Wickstrom

Thomas Jefferson University,

Philadelpha, PA)

Gene-Specific Therapy of Breast and

Pancreatic Cancer

Thomas Jefferson Univ.; Barbara Shaw, Duke Univ.; Marvin Caruthers, Univ. of Colorado; J. Dirk Iglehart, Duke Univ.; Rudolph Juliano, Univ. of North Carolina

U19 CA53001

09/30/90-09/29/01

Frederick A. Valeriote, Ph.D.

Wayne State University School

of Medicine, Detroit, MI

(replaced by:

Charles Grieshaber,

Jerome Horwitz, Wayne State Univ.)

Discovery of New Anticancer Agents from Natural Products

Richard Moore, Univ. of Hawaii; Joseph Hoffmann, Univ. of Arizona; Thomas Corbett, Wayne State Univ.,

Eli Lilly Corp.

U19 CA67760

09/30/95-09/29/01

Daniel D. Von Hoff, M.D.

The University of Texas Health Science Center at San Antonio

San Antonio, TX

Telomere and Telomerase Interactive Agents

Shih-Fong Chen, Bradford Windle, Cancer Therapy and Research Ctr.; Laurence Hurley, Univ. of Texas at Austin

U01 CA48405

08/01/88-07/31/91

Geoffrey Wahl, Ph.D.

The Salk Institute for Biological Studies

San Diego, CA

Detection and Curing of Amplified Genes in Human Cancer

Daniel D. Von Hoff, Univ. of Texas Health Science Ctr. of San Antonio